Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Related Questions
In resected N2 NSCLC, what nodal pathologic characteristics prompt you to recommend PORT?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
